Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of HRS-5965 in Healthy and Renal Impaired Subjects
NCT05505955Phase 1Completed
- Sponsor
- Chengdu Suncadia Pharmaceuticals
- Start
- Oct 2022
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HRS-5965 in Glomerulonephritis (GN) (3 arms), sponsored by Chengdu Suncadia Pharmaceuticals. Primary endpoint: Incidence and severity of adverse events up to 24 days. Started Oct 2022; status: completed.
02
Drugs
HRS-5965
03
Conditions
Glomerulonephritis (GN)
Beyond the preview
Go deeper on NCT05505955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05505955.